Determinants of the Availability of Hepatitis C Testing Services in Opioid Treatment Programs: Results From a National Study

Guardat en:

Dades bibliogràfiques
Publicat a:	American Journal of Public Health vol. 104, no. 6 (Jun 2014), p. E75-E82
Autor principal:	Frimpong, Jemima A
Altres autors:	D'Aunno, Thomas, Jiang, Lan
Publicat:	American Public Health Association
Matèries:	Financing, Government > statistics & numerical data Health Care Surveys Health Services Accessibility > organization & administration Health Services Accessibility > statistics & numerical data Hepatitis C > diagnosis Humans Opiate Substitution Treatment > statistics & numerical data Opioid-Related Disorders > complications Substance Abuse Treatment Centers > organization & administration Substance Abuse Treatment Centers > statistics & numerical data United States United States > US Substance abuse treatment Methadone Drug abuse Hepatitis Medical tests Health care industry Infections Validity Trends Drug use Response rates Disease prevention Mental health Health services Onsite Narcotics Mental health care Public health Opioids Treatment programs Medical treatment Referrals Diagnostic tests Availability Substance abuse Prevention programs Buprenorphine Blood diseases Social
Accés en línia:	Citation/Abstract Full Text Full Text - PDF
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Descripció
Resum:	We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability of HCV testing in opioid treatment programs. We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability of HCV testing in opioid treatment programs.
ISSN:	0090-0036 0002-9572 0271-4353 0273-1975
Font:	ABI/INFORM Global